Skip to content

Q/C Technologies, Inc.

QCLS· NasdaqCore metricsCIK 1321834

In vitro & in vivo diagnostic substances19 peers

Last sale
Nov 9, 2026 · +6.10%
Market cap
$3.19M
8.5M shares
Filings
606
-$1.89K
Q2 2020−5.3% FY19 yoy
-$941.79K
Q3 2026N/M FY25 yoy
-$2.57M
Q3 2026N/M FY25 yoy
-$10.82M
FY 2025derivedN/M FY25 yoy
-$0.14
Q3 2026N/M FY25 yoy
$2.59M
Q3 2026+470.0% FY25 yoy
$3.19M
—
—
0.2×
-338.53%
—

FY2025 figures · derived

Price

$0.375987.80%$2.7041past year
Nov 9, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.58MFY 2019
$4.43M0FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019
PeriodEndedValueKindSource trail
FY 20192019-12-31$1,577,033reported
FY 20182018-12-31$1,665,570reported
FY 20172017-12-31$3,354,712 revisedreported
FY 20162016-12-31$2,960,912reported
FY 20152015-12-31$2,115,050reported
FY 20142014-12-31$4,427,174reported
FY 20132013-12-31$3,577,851reported

In vitro & in vivo diagnostic substances

Q/C Technologies, Inc. is the 18th largest of the 20 covered companies the SEC files under this code, by market cap. SIC 2835

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Q/C Technologies, Inc. · CIK 1321834 · Engraved from SEC EDGAR